CAPMATINIB (INC280) IN MET Delta EX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY
Year: 2019
Type: article
Authors: Heist, Rebecca S., Seto, Takashi, Han, Ji-Youn, Reguart, Noemi, Garon, Edward B., Groen, Harry J. M., Tan, Daniel S. W., Hida, Toyoaki, de Jonge, Maja, Orlov, Sergey V., Smit, Egbert F., Souquet, Pierre-Jean, Vansteenkiste, Johan, Le Mouhaer, Sylvie, Robeva, Anna, Waldron-Lynch, Maeve, Giovannini, Monica, Wolf, Juergen
Institutions: Harvard University, Massachusetts General Hospital, National Hospital Organization Kyushu Cancer Center, National Cancer Center, Hospital Clínic de Barcelona, Universitat de Barcelona, University of California, Los Angeles, University of California System, National Cancer Centre Singapore, Aichi Cancer Center, Erasmus MC, Erasmus MC Cancer Institute, Erasmus University Rotterdam, First Pavlov State Medical University of St. Petersburg, The Netherlands Cancer Institute, Hospices Civils de Lyon, Hôpital Lyon Sud, Universitair Ziekenhuis Leuven, KU Leuven, Novartis (Switzerland), University of Cologne, University Hospital Cologne
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3011710986